Celula

Celula, Inc. is a diagnostic testing services company dedicated to significantly improving the diagnostic accuracy of serious diseases, thereby providing better patient care and improving outcomes. Celula's unique and cost-effective "Integrated Diagnostic Accuracy" platform (IDA) consists of a combination of proprietary and non-proprietary algorithms and technologies, which together achieve higher accuracy compared to current tests. IDA test results have the potential to deliver higher Positive Predictive Values (PPV) for the presence of disease and greatly reduce unnecessary interventions caused by false-positive results. Actionable outcomes will be provided in the form of customized Integrated Patient Reports (IPR) to assist decision-making by patients and physicians. The company’s initial products will focus on enhancing diagnostic accuracy for major women’s health conditions, particularly in gynecological cancers and non-invasive prenatal diagnostics.